Apple allergy is common in patients allergic to birch pollen, and this is defined as 'birch-apple syndrome'. Allergens responsible for cross-reactivity belong to the pathogenesis-related-10 family, and high homology in the amino acid sequences of the major allergens Bet v 1 from birch and Mal d 1 from apple has been demonstrated. Here we review the literature on the treatment of birch-apple syndrome by allergen immunotherapy. The only allergen immunotherapy method available thus far is based on the administration of birch-pollen extracts, through the subcutaneous or sublingual route, to induce tolerance to Bet v1 and to the homologous allergen Mal d 1. However, the studies performed thus far show modest efficacy, and thus other methods of immunotherapy should be investigated.
Allergen immunotherapy for birch-apple syndrome: what do we know? / I. Cristoforo, R. Erminia, M. Marina, R. Marina, E. Pastorello. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 9:15(2017 Nov), pp. 1271-1278.
|Titolo:||Allergen immunotherapy for birch-apple syndrome: what do we know?|
|Parole Chiave:||allergen immunotherapy; apple; birch pollen; birch-apple syndrome; cross-reactivity; pathogenesis-related proteins|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||nov-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.2217/imt-2017-0040|
|Appare nelle tipologie:||01 - Articolo su periodico|